3 Huge Red Flags From Tilray's Q1 Earnings Report
Last week, Tilray Brands (NASDAQ:TLRY) reported its first-quarter numbers for fiscal 2027. While management boasted of its record-breaking numbers and diversified business, investors shouldn't buy the hype at all. Tilray has been a bad investment for many years, and acquisitions may have boosted its revenue, but they haven't changed the story around this troubling marijuana stock . It's a bad buy, and the three numbers below from its earnings report only confirm that. Image source: Getty Images. Continue reading